TCTR20180820002
Recruiting
Phase 2
Efficacy of 0.05%topical everolimus in the treatment of adenoma sebaceum in tuberous sclerosis
Dermatology division, Department of internal medicine, King Chulalongkorn Memorial Hospital0 sites15 target enrollmentAugust 20, 2018
Conditionsadenoma sebaceum
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- adenoma sebaceum
- Sponsor
- Dermatology division, Department of internal medicine, King Chulalongkorn Memorial Hospital
- Enrollment
- 15
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\-patients with adenoma sebaceum
Exclusion Criteria
- •\-pregnancy
- •\-allergic reaction to everolimus
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Clinical effects of everolimus in the subjects with autism spectrum disprders (ASD) in relation to tuberous sclerosis.there are a few individuals with TSC with SEGA who exhibite ASD symptoms.JPRN-jRCT1090220258Kunio Yui20
Completed
Phase 2
Efficacy and Safety of Everolimus in Patients with Unresectable or Metastatic Renal Cell Carcinomarenal cell carcinomaJPRN-UMIN000008769Tokyo Afinitor Clinical Trial Group - RCC(TACT-R)120
Not yet recruiting
Phase 2
Efficacy and Safety of Everolimus in Patients with Non-Clear Cell Renal Cell Carcinomaon-clear cell renal cell carcinomaJPRN-UMIN000006248Yamaguchi University Graduate School of Medicine , Department of Urology10
Active, not recruiting
Phase 1
Topical Everolimus versus placebo for the treatment of facial angiofibromas in patients with tuberous sclerosis complex.EUCTR2018-002531-18-FRHospices Civils de Lyon146
Completed
Phase 2
A phase 2 trial of EVERolimus alternating with SUNitinib as first line therapy for advanced renal cell carcinomaACTRN12609000643279The University of Sydney55